Specialties:
Neurologist, Neuromuscular Specialist
Address:
200 Old Country Road, Mineola, NY 11501
Education:
Medical School - Albany Medical College
1978-1979 Internship, Framingham Union Hospital, Framingham, MA
1979-1983 Psychiatry Residency and Fellowship, Boston University Medical Center, Boston, MA
Professional Memberships:
American Academy of Neurology, Nassau Academy of Medicine, New York State Multiple Sclerosis Consortium, American Medical Association, American Academy of Neurology, New York State Medical Society, Nassau County Medical Society, Clinical Advisory Committee Long Island MS Society
Awards and Publications:
Neutralizing Antibodies To 500 µg Interferon Beta-1b: 28-Month Results Of The Ideas Extension Trial. MH Gottesman, S Friedman-Urevich, Sharon, E Boylan and D Cheng. Multiple Sclerosis 16(1) 78-80, 2010., BENEFIT Five Years On. Gottesman, Malcolm. Neurology Insights Europe. March 2009. Page 33-36., Interferon beta-1b (Betaseron/Betaferon) is well tolerated at a dose of 500ug: interferon dose escalation of safety (IDEAS). MH Gotteman and S Friedman-Urevich. Multiple Sclerosis 2006; 12: 271-278, Gottesman, M. Carotid Artery Dissection and Stroke Caused by an Airbag Injury. The American Journal of Emergency Medicine, July 2002 Issue., High Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis: 2-Year Follow-up (Investigational New Drug No. 65863). Gladstone, D; Peyster, R; Baron, E; Friedman-Urevich, S; Sibony, P; Melville, P; Gottesman, M; American Journal of Therapeutics. October 14, 2009., Lam S, Wang S, Gottesman M. Expert Opinion: Interferon B1b for the treatment of multiple sclerosis. Drug Metab. Toxicol. (2008) 4(8): 1-7.
Board certifications:
American Board of Psychiatry and Neurology
Hospital affiliations:
Winthrop-University Hospital
About:
Dr. Malcolm H. Gottesman is an attending neurologist on full-time faculty at Winthrop-University Hospital where he serves as Chief of the Division of Neurology
and Co-director of ...